BRIEF—Deciphera gains approval of Qinlock in the UK

Deciphera Pharmaceuticals today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Qinlock (ripretinib) in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

“The approval of Qinlock in the UK is an important milestone for patients with advanced GIST who have been waiting for a new treatment option,” said Steve Hoerter, president and chief executive of Deciphera.

“The results from the INVICTUS study underscore the potential for Qinlock to transform the treatment of advanced GIST and establish a new standard of care in the UK for fourth-line GIST,” he added.

Qinlock was approved in the USA, Canada and Australia in 2020, and was recommended for approval in the European Union in September this year.